Published in Cancer Weekly, January 14th, 2003
K. J. Radford and colleagues at Cancer Research UK in Great Britain and Harvard Medical School in the U.S. engineered E. coli to express both LLO and OVA cytoplastic proteins. In murine dendritic cells, the recombinant E. coli delivered the OVA Kb-restricted epitope SIINFEKL for MHC class I presentation. However, delivery of the OVA 323-339 I-Ab-restricted epitope for MHC class II...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.